Ikonisys publishes its Full-Year Financial Results for 2022 and provides an update on its latest developments

Regulatory News:

Ikonisys SA (Code ISIN: FR00140048X2 / Ticker: ALIKO), a company specializing in the early and accurate detection of cancer with a unique and fully-automated solution for medical diagnostic labs, today announced its annual audited results for the year ending December 31, 2022, as approved by the Board of Directors on April 28, 2023 and provided an update on its latest developments.

Mario Crovetto, CEO of Ikonisys, said: “2022 has been another very important year for our company. In the initial part of the year we started to commercialize Ikoniscope20, our fully automated solution for molecular diagnostics, used especially by pathology laboratories for oncological FISH testing. In December we announced availability of Ikoniscope20max, the Ikoniscope version that is particularly adapt for laboratories that process high volumes. In addition to proceeding with implementation of our commercial strategy we further strengthened our technology platform through targeted R&D programs. In particular we are working in the very promising CTC sector for early cancer detection and treatment monitoring. Moreover, we continue to update and expand our application portfolio and to integrate artificial intelligence into our platform. In short, during 2022 and early 2023 Ikonisys consistently progressed along the path outlined at the time of our July 2021 IPO and has efficiently laid the groundwork for sales growth.”

2022 Full-year results vs. 2021 - Simplified consolidated income statement audited

Euros		FY 2022			FY 2021
Net Sales		616,866			365,144
Other income		318,352			177,557
Cost of goods sold		(183,413)			(70,642)
Operating expenses		(3,383,538)			(1,036,291)
Operating income / (loss)